CHRS · NASDAQ
Coherus Oncology, Inc.
$0.99 -0.02 (-1.98%)
Company overview
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta (a long-acting granulocyte-colony stimulating factor); LOQTORZI, a next-generation programmed death receptor-1 (PD-1) inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin G1 (IgG1) monoclonal antibody targeting interleukin-27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an anti-ILT4 monoclonal antibody for solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $153M
- Employees
- 228
- Headquarters
- Redwood City, CA
- Website
- coherus.com
- CEO
- Dennis Lanfear
- Listed
- November 6, 2014
- P/E
- -0.77
- Dividend yield
- 0.00%
Company financials
- Revenue
- $46.9M
- Gross profit
- $28.1M
- Operating income
- -$170M
- EBITDA
- -$166M
- Net income
- -$152M
- EPS
- -$1.28
- Total assets
- $266M
- Total debt
- $54.4M
- Gross margin
- 60.04%
- Net margin
- -323.49%
- Earnings yield
- -130.61%
No geographic segmentation.
Showing FY 2025
CHRS
1D
NASDAQ
O1.03H1.04L0.99C1.01-0.04 (-3.81%)Vol641.45K